Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Shield Therapeutics plc    STX   GB00BYV81293


Delayed Quote. Delayed London Stock Exchange - 07/08 11:35:20 am
89.5 GBX   +4.68%
06/18SHIELD THERAPEUTICS : Results of 2020 Annual General Meeting
06/03SHIELD THERAPEUTICS : Feraccru®/Accrufer® publications
05/28SHIELD THERAPEUTICS : Investor presentations
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shield Therapeutics : Appointment of Chairman

share with twitter share with LinkedIn share with facebook
05/26/2020 | 02:38am EDT

Shield Therapeutics plc

('Shield' or the 'Group' or the 'Company')

Appointment of Chairman

London, UK, 26 May 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer®(ferric maltol),announces the appointment of Hans Peter Hasler as non-executive Chairman of the Company with effect from the Annual General Meeting ('AGM') on 18 June 2020.

As announced on 21 May 2020, James Karis, the Company's current Chairman, informed the Company that he would not seek re-election and would be stepping down at the AGM on 18 June 2020. Hans Peter Hasler has therefore been appointed with effect from the AGM. Hans Peter joined Shield's Board of Directors in July 2018 and has served as Chairman of the Nomination Committee and a member of the Audit Committee. Hans Peter has prior executive experience including as Chief Operating Officer at both Elan Corporation and Biogen Inc. as well as Chief Marketing Officer of Wyeth Pharmaceuticals, Radnor, PA. He is non-executive Chairman of the Board of HBM Healthcare Investments AG, Zug/Switzerland and a non-executive director of Minerva Neuroscience Inc., Boston.

Hans Peter Hasler said: 'I am delighted to have been appointed as Chairman of Shield at a critical time for the Group. Feraccru®/ Accrufer® is an excellent product with enormous potential and I look forward to continuing to help the Group find ways of making it available to the widest possible number of patients and to translating that into value for shareholders. I also look forward to working with the rest of the Board and the management team in these endeavours.'

Tim Watts, CEO of Shield Therapeutics, said:'I am very pleased to see Hans Peter appointed as our Chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally.'

For further information please contact:

Shield Therapeutics plc


Tim Watts, CEO

+44 (0)20 7186 8500

Karen Chandler Smith, Investor Relations

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

Geoff Nash/Matt Radley/Alice Lane

+44 (0)20 7220 0500

Financial PR & IR Advisor

Walbrook PR

+44 (0)20 7933 8780 or shield@walbrookpr.com

Paul McManus/Lianne Cawthorne

+44 (0)7980 541 893 / +44 (0)7584 391 303

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group's lead product, Feraccru®/ Accrufer® has exclusive IP rights until the mid-2030s andis approved for the treatment of iron deficiency with or without anaemia in adultsin the European Union, the United States and Switzerland. In Europeit is marketed as Feraccru®with commercialisation led by Norgine BVand in the USA the productwill be marketed as Accrufer® with Shield currently in the process of selecting a commercialisation partner. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. For more information please visit www.shieldtherapeutics.com

About Feraccru®/Accrufer®

Feraccru®/Accrufer® is a novel, stable, non-salt based oral therapyfor adults with iron deficiency with or without anaemia that has been shown to be an efficacious and well-tolerated therapy in a range of controlled phase 3 trials, and offers a compelling alternative to IV iron for those patients unable totolerate salt-based oral iron therapies and wish to avoid the complexities of infusion-based iron therapies.

When salt-based oral iron therapies are ingested they can cause a range of mild-to-severe gastrointestinal tract (GI) adverse events, including nausea, bloating and constipation through the release and subsequent reactivity of free iron in the GI tract, leading to poor tolerability, reduced patient compliance and ultimately treatment failure. Feraccru®/Accrufer® is not an iron saltand, as a result, it does not routinely cause the same treatment-limiting intolerance issues of salt-based iron therapies,whilst theiron from the ferric maltol molecule can be readily absorbed.

Prior to Feraccru®/Accrufer®, IV iron therapies were the only realistic alternative treatment option for iron deficient patientswith or without anaemiaintolerant of or unwilling to be treatedsalt-based oral iron therapies. However, use of such an invasive, costly, inconvenient and complex to administer treatment option, which is associated with potentially life-threatening and spontaneous hypersensitivity reactions, means there remains a clear unmet medical need for these patients to have access to an effective therapy that is well tolerated, convenient and does not require hospital-based administration. Feraccru®/Accrufer® meets those requirements.

About Iron Deficiency

The WHO states that iron deficiency is the most common and widespread nutritional disorder in the world. As well as affecting a large number of women and children in non-industrialized countries, it is the only nutrient deficiency which is also significantly prevalent in virtually all industrialised nations. There are no current global figures for iron deficiency but, using anaemia as an indirect indicator, it can be estimated that most preschool children and pregnant women in non-industrialised countries, together with at least 30-40% in industrialized countries, are iron deficient.


Shield Therapeutics plc published this content on 26 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 May 2020 06:37:09 UTC

share with twitter share with LinkedIn share with facebook
06/18SHIELD THERAPEUTICS : Results of 2020 Annual General Meeting
06/03SHIELD THERAPEUTICS : Feraccru®/Accrufer® publications
05/28SHIELD THERAPEUTICS : Investor presentations
05/26SHIELD THERAPEUTICS : Appointment of Chairman
05/22SHIELD THERAPEUTICS : 2019 Annual Report and 2020 AGM Notice
05/22SHIELD THERAPEUTICS : Preliminary Results for the Year Ended 31 December 2019
05/20SHIELD THERAPEUTICS : Notice of results
05/19SHIELD THERAPEUTICS : Notice of Results
05/04SHIELD THERAPEUTICS : Business and trading update
05/01SHIELD THERAPEUTICS : Business and trading update
More news
Sales 2020 10,6 M 13,4 M 13,4 M
Net income 2020 1,15 M 1,45 M 1,45 M
Net cash 2020 1,07 M 1,35 M 1,35 M
P/E ratio 2020 92,6x
Yield 2020 -
Capitalization 105 M 132 M 132 M
EV / Sales 2019
EV / Sales 2020 9,77x
Nbr of Employees 20
Free-Float 23,7%
Duration : Period :
Shield Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIELD THERAPEUTICS PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 4
Average target price 275,00 GBX
Last Close Price 89,50 GBX
Spread / Highest target 291%
Spread / Average Target 207%
Spread / Lowest Target 123%
EPS Revisions
Timothy William Watts Chief Executive Officer & Director
Hans-Peter Hasler Non-Executive Chairman
Peter Llewellyn-Davies Independent Non-Executive Director
Rolf K. Hoffmann Independent Non-Executive Director
Christian Schweiger Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.47.29%31 379
GENMAB A/S53.43%22 516